Commercialization, • 9/19/25 What Matters to Payers: Conversations You Should Start During Phase 2 Previous Designing Trials with the End in Mind: Building Market Access into Rare Disease Clinical Development Next Real-World Evidence That Matters: A Hands-On Workshop in Building Credible Value Stories You Might Also Like AI-Driven Patient Identification and Recruitment Beyond Biotech: The Rise of Nontraditional Sponsors in Rare Disease Trials Rare Isn’t Small: Incorporating Operational Excellence into Global, Multisite Rare Disease Trials Patient-Centric Commercialization: Integrating Patient Voices into Market Access Strategies Case Studies in Rare Disease Commercialization: Lessons Learned
Commercialization, • 9/19/25 What Matters to Payers: Conversations You Should Start During Phase 2 Previous Designing Trials with the End in Mind: Building Market Access into Rare Disease Clinical Development Next Real-World Evidence That Matters: A Hands-On Workshop in Building Credible Value Stories You Might Also Like AI-Driven Patient Identification and Recruitment Beyond Biotech: The Rise of Nontraditional Sponsors in Rare Disease Trials Rare Isn’t Small: Incorporating Operational Excellence into Global, Multisite Rare Disease Trials Patient-Centric Commercialization: Integrating Patient Voices into Market Access Strategies Case Studies in Rare Disease Commercialization: Lessons Learned
